ArticleTherapeutic advances in medical oncology2022

Cost-effectiveness of enfortumab vedotin in previously treated advanced urothelial carcinoma.

Qiuji Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.